128173-50-2

Usage

Uses

Used in Pharmaceutical Synthesis:
N-(4-Cyanobutyl)-N-(phenylmethoxy)carbamic acid tert-butyl ester is used as an intermediate in the synthesis of Deferoxamine-d7 TFA Salt (D228982), a labelled Deferoxamine Mesylate (D228980). N-(4-Cyanobutyl)-N-(phenylmethoxy)carbamic acid tert-butyl ester is an iron chelating agent utilized in the therapy for patients with sickle cell diseases and iron overload conditions.
Used in Antioxidant and Neuroprotective Applications:
Studies suggest that N-(4-Cyanobutyl)-N-(phenylmethoxy)carbamic acid tert-butyl ester can exert potential antioxidant and neuroprotective effects in stroke patients. Its ability to chelate iron and modulate oxidative stress pathways may contribute to its therapeutic potential in neurodegenerative conditions.

InChI:InChI=1/C17H24N2O3/c1-17(2,3)22-16(20)19(13-9-5-8-12-18)21-14-15-10-6-4-7-11-15/h4,6-7,10-11H,5,8-9,13-14H2,1-3H3

Upstream product

• 13249-56-4 4-chloro-valeronitrile 
• 79722-21-7 tert-butyl N-(benzyloxy)carbamate 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6280-87-1 δ-chlorovaleronitrile 

Downstream Products

• 153492-12-7 5-(Benzyloxy)-11-(tert-butoxycarbonyl)-4-oxo-5,11-diazaundecanoic acid 
• 112972-60-8 bisucaberin 
• 129245-26-7 6,17-bis(benzyloxy)-1,6,12,17-tetraazacyclodocosane-2,5,13,16-tetrone 
• 129245-25-6 21-amino-5,16-bis(benzyloxy)-4,12,15-trioxo-5,11,16-triazaheneicosanoic acid 
• 129245-22-3 N-(4-cyanobutyl)-3-<<5-<(benzyloxy)-tert-butoxy-carbonylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid 
• 129245-23-4 N-(4-cyanobutyl)-3-<<5-<(benzyloxy)amino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid 
• 112139-60-3 N-(4-Cyanobutyl)-N-(benzyloxy)succinamic Acid 
• 284666-59-7 tetra-O-benzyl danoxamine 
• 284666-57-5 28-(tert-butoxycarbonyl)-1,6,17,29-tetrakis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22,28-pentaazaoctacosane 
• 284666-64-4 1,6,17,29-tetrakis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22,28-pentaazaoctacosane 
• 284666-55-3 5,16,21-tris(benzyloxy)-4,12,15-trioxo-5,11,16-triazahenicosanoic acid 
• 284666-53-1 17-(tert-butoxycarbonyl)-1,6,17-tris(benzyloxy)-7,10-dioxo-6,11,17-triazaheptadecane 
• 284666-62-2 1,6,17-tris(benzyloxy)-7,10-dioxo-6,11,17-triazaheptadecane 
• 952489-10-0 methyl (9S)-3-(acetyloxy)-9-{formyl[(1R)-1-phenylethyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxylate 

Relevant academic research and scientific papers

Design, Synthesis and Evaluation of AdSS Bisubstrate Inhibitors

Many cancers lack the expression of methylthioadenosine phosphorylase (MTAP). These cancers require adenylosuccinate synthetase (AdSS) for nucleic acid synthesis. By inhibiting adenylosuccinate synthetase, we potentially have a new therapeutic agent. Bisubstrate inhibitors were synthesized and evaluated against purified AdSS. The best activity was obtained with adenosine bearing a four-carbon linker that connects the N-formyl-N-hydroxy moiety to the 6-position of the purine nucleoside.

ANTIBACTERIAL SIDEROMYCINS

A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderophore; or pharmaceu

The synthesis of tetrahydropyridopyrimidones as a new scaffold for HIV-1 integrase inhibitors

An efficient synthesis of methyl 9-amino-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxylate as a late stage intermediate for a new class of HIV-1 integrase inhibitors is described. After construction of the bicyclic core scaffold,

TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4,

Total synthesis of the siderophore Danoxamine

The total synthesis of the linear trihydroxamate siderophore, Danoxamine, is described. Danoxamine is a siderophore component of the naturally occurring siderophore-drug conjugates Salmycin A-D. The synthesis of Danoxamine features a series of coupling re

Method for synthesis of desferrioxamine B, analogs and homologs thereof

Synthesis of desferrioxamine B and analogs and homologs thereof beginning with O-protected, N-protected hydroxylamine, which is N-alkylated to produce a protected N-4-cyanoalkylhydroxylamine which is acylated with a suitable anhydride. The resulting half-

Method for the synthesis of desferrioxamine B and analogs thereof

Disclosed is a synthesis of desferrioxamine B and analogs and homologs thereof beginning with the generation of the O-protected N-(4-cyanobutyl)hydroxylamine which is acylated at the O-benzylhydroxylamine nitrogen with either succinic or acetic anhydride. The resulting half-acid amide or amide respectively, is subjected to a series of high yield condensations and reductions which provide desferrioxamine B in 45% overall yield. Finally, a desamino analog of desferrioxamine is prepared in order to demonstrate the synthetic utility of the scheme as applied to desferrioxamine derivatives.

THE TOTAL SYNTHESIS OF BISUCABERIN

The first total synthesis of 6,17-dihydroxy-1,6,12,17-tetraazacyclodocosane-2,5,13,16-tetrone (bisucaberin) is presented.The synthetic scheme employed in this study illustrates the utility of O-benzyl-N-(tert-butoxycarbonyl)-N-(4-cyanobutyl)hydroxylamine